Literature DB >> 31339212

Real-world versus trial patients with transthyretin amyloid cardiomyopathy.

Marco Canepa1,2, Giacomo Tini1,2, Beatrice Musumeci3, Francesco Cappelli4, Agnese Milandri5, Roberta Mussinelli6, Camillo Autore3, Federico Perfetto4, Claudio Rapezzi5, Stefano Perlini6.   

Abstract

Entities:  

Year:  2019        PMID： 31339212     DOI： 10.1002/ejhf.1563

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN： 1388-9842            Impact factor:   15.534


× No keyword cloud information.
  4 in total

Review 1.  99m Technetium-pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy.

Authors:  Nobuhiro Tahara; Olivier Lairez; Jin Endo; Atsushi Okada; Mitsuharu Ueda; Tomonori Ishii; Yoshinobu Kitano; Hahn-Ey Lee; Eleonora Russo; Toru Kubo
Journal:  ESC Heart Fail       Date:  2021-11-29

2.  Beta-Adrenergic Antagonist Tolerance in Amyloid Cardiomyopathy.

Authors:  Stuart Ramsell; Carlos Arias Bermudez; Cyril Ayuk Mbeng Takem Baiyee; Brandon Rodgers; Samir Parikh; Salem Almaani; Nidhi Sharma; Samantha LoRusso; Miriam Freimer; Elyse Redder; Naresh Bumma; Ajay Vallkati; Yvonne Efebera; Rami Kahwash; Courtney M Campbell
Journal:  Front Cardiovasc Med       Date:  2022-07-11

3.  Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.

Authors:  Mark H Rozenbaum; Andrea Garcia; Daniel Grima; Diana Tran; Rahul Bhambri; Michelle Stewart; Benjamin Li; Bart Heeg; Maarten Postma; Ahmad Masri
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2022-08-17

4.  Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic.

Authors:  Krister Lindmark; Björn Pilebro; Torbjörn Sundström; Per Lindqvist
Journal:  ESC Heart Fail       Date:  2020-11-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.